WL276
/ Beijing Imunopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 15, 2024
WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
CAR T-Cell Therapy • New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD276
1 to 1
Of
1
Go to page
1